Journal · Updated 2026-08-11

Who Still Sells Compounded Tirzepatide in 2026: The 503A-Pathway Map

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

What "503A survivor" actually requires

Three things, none optional. A named, licensed pharmacy — because the 503A lane is defined by a specific pharmacy filling a specific prescription, and a program that will not say which pharmacy fills yours cannot demonstrate it operates in the lane at all; the FDA's June 2026 warning letters cited exactly that concealment. A patient-specific prescription with documented clinical need — the individualized evaluation is the lane's legal substance, which is why "no prescription needed" ends any evaluation instantly, and why intake flows that collect payment before qualification deserve the side-eye our provider records give them. And per-prescription scale — the structural reason the surviving market cannot look like the shortage-era market, and the reason post-shortage 503B production drew an FDA warning (reported May 18, 2026) rather than a pass. The fifteen-minute verification workflow tests all three; the enforcement record holds the dated history behind them.

The map, from the database

Drawn from current records, statuses attached. Named-pharmacy programs — the verifiable core: Sprout Health names Foothills and Promise as its partner pharmacies; Henry Meds' dispensing pharmacy (Tailor Made Compounding) is printed on its materials and provided pre-order on request, though its tirzepatide is oral tablets only; NexLife names a multi-pharmacy network on its record. These are the programs where step one of verification succeeds. Rankable programs with undisclosed pharmacies — real published maintenance prices, unverifiable supply chains: the current tirzepatide board runs from the one-sixty-nine promotional floor through the flat mid-market (PlexusDx's provider-stated two forty-nine, Sprout's two ninety-nine, Peak's three forty-nine, Fridays' three fifty-nine, Willow's flat three ninety-nine in thirty-three states) to the four-forty-nine tier — each carrying its evidentiary status in the database and its head-to-heads in the matrix. Recorded but unrankable — the honesty tier: Curex's widely-quoted one ninety-nine is a starter-dose rate with no published maintenance ladder (the very comparison that badges it "lowest all-in" says so in the next sentence); Embody's ninety-nine-dollar advertised figure sits below the compliant cost floor with dose and fees unestablished; Gimme Care's one sixty-three is a three-month-plan rate with no month-to-month figure; Henry's oral tablets cap at six milligrams daily and fail the injection basis entirely. Recorded, dated, excluded from rankings — because a number you cannot hold a program to is not a price. The brand lane beside it all: LillyDirect's FDA-approved vials at two ninety-nine to four forty-nine on the forty-five-day clock, which no regulatory outcome touches.

How to use the map

Pick the lane before the price. If verifiability is the priority, start with the named-pharmacy column and run the fifteen-minute check on the name you're given. If price is the priority, the rankable column's computed ordering is the honest board — promotions labeled, statuses shown, the change ledger recording every move. If an advertised figure from the unrankable column tempts you, the two-question test from the ad-anatomy piece applies before any payment: the all-in maintenance price, in writing, outside the funnel. And whatever lane you pick, the contingency questions belong in your first conversation with the program — because the market that survived 2025's narrowing is the market that answers them, and the part that couldn't is the part that didn't survive.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.